comparemela.com
Home
Live Updates
Nature Medicine Publishes Two Studies Highlighting Signateras Clinical Utility in Patients with Gastrointestinal Malignancies -January 25, 2024 at 07:04 am EST : comparemela.com
Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal Malignancies -January 25, 2024 at 07:04 am EST
AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors
PANDA study shows...
Related Keywords
Netherlands ,
California ,
United States ,
San Carlos ,
Texas ,
Christopher Haqq ,
Alexey Aleshin ,
Netherlands Cancer Institute ,
Clinical Laboratory Improvement Amendments ,
Elicio Therapeutic Inc ,
Natera Inc ,
Nasdaq ,
Nature Medicine ,
Elicio Therapeutic ,
Myriam Chalabi ,
Markets ,
comparemela.com © 2020. All Rights Reserved.